Effects of Curcumin on Tumour Necrosis Factor‐<i>α</i> and Interleukin‐6 in the Late Phase of Experimental Acute Pancreatitis

Gülçubuk, Ahmet; Altunatmaz, Kemal; Sönmez, Kıvılcım; Haktanir-Yatkin, D.; Uzun, Hafize; Gürel, Aydın; Aydın, Salih

doi:10.1111/j.1439-0442.2006.00786.x

Cited by 68 publications

(39 citation statements)

References 32 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To prepare the stock solution of curcumin, microbiologically-tested ethanol and dimethyl sulphoxide (DMSO) were used. Ethanol was prepared made up to a 9% solution (Gulcubuk et al 2006). Curcumin was used at doses of 0.5%, 1% and 2%.…”

Section: Methodsmentioning

confidence: 99%

Antimicrobial effects of curcumin against L. monocytogenes, S. aureus, S. Typhimurium and E. coli O157:H7 pathogens in minced meat

Altunatmaz¹,

Kahraman²,

Büyükünal³

et al. 2016

Vet. Med. - Czech

View full text Add to dashboard Cite

ABSTRACT:The aim of this study was to determine the antimicrobial efficacy of curcumin, one of the active components of the Curcuma longa (turmeric) plant, against food pathogens in a minced meat medium. Salmonella Typhimurium ATCC 14028, Listeria monocytogenes ATCC 7644, Escherichia coli O157:H7 ATCC 33150 and S. aureus ATCC 25923 strains were used as food pathogens. Minimum inhibitory concentrations (MICs) were determined using the macrodilution method. MIC values for curcumin were found to be 125 µg/ml for L. monocytogenes and S. aureus, and 250 µg/ml for S. Typhimurium and E. coli O157:H7. Food pathogens were added to the minced meat at 10 4 CFU/g (including the control group) and curcumin at doses of 0.5%, 1% and 2% (except the control). The curcumin-supplemented minced meat and control were analysed 0-7 days later. At the end of seven days, it was seen that the 2% dose of curcumin had lowered L. monocytogenes and S. aureus counts by approximately 3 log CFU/g, and E. coli O157:H7 and S. Typhimurium counts by approximately 2 log CFU/g; the 1% dose had lowered L. monocytogenes, S. aureus, E. coli O157:H7 and S. Typhimurium counts by approximately 2 log CFU/g; and that the 0.5% curcumin dose had lowered L. monocytogenes and S. aureus count by approximately 2 log CFU/g, and E. coli O157:H7 and S. Typhimurium count by approximately 1 log CFU/g. Changes in bacterial counts were found to be statistically significant (P ≤ 0.05). It was observed that antibacterial effect increased in direct proportion to dose, while sensory approval decreased. In this study, 0.5% and 1% curcumin doses were determined to be sensorily acceptable. It was concluded that, in view of the scientific benefits and antimicrobial efficacy of curcumin, it may be used instead of, or in smaller doses together with preservative additives in foods where colour change is not important.

show abstract

Section: Methodsmentioning

confidence: 99%

Antimicrobial effects of curcumin against L. monocytogenes, S. aureus, S. Typhimurium and E. coli O157:H7 pathogens in minced meat

Altunatmaz¹,

Kahraman²,

Büyükünal³

et al. 2016

Vet. Med. - Czech

View full text Add to dashboard Cite

show abstract

“…• Significantly lowered the serum TNF-a and IL-6 levels in rat model of acute pancreatitis (Gulcubuk et al, 2006).…”

Section: Figurementioning

confidence: 99%

“…Decreased TNF-a levels have also been noted in tumour-bearing animals treated with this polyphenol (Leyon and Kuttan, 2003). In addition to cancer, down-regulation of TNF-a by curcumin has been associated with protection from various pro-inflammatory diseases, including sub-chronic inflammation (Nandal et al, 2009;Nishida et al, 2010), cardiovascular diseases (Yao et al, 2004;Mito et al, 2011;Avci et al, 2012), diabetes (Jain et al, 2009;El-Azab et al, 2011;El-Moselhy et al, 2011), acute pancreatitis (Gulcubuk et al, 2006), enterocolitis (Jia et al, 2010), enteritis (Song et al, 2010), prostatitis (Zhang et al, 2010b), diabetic neuropathy (Sharma et al, 2007b), hepatic injury (Yun et al, 2010), Th1-type ileitis (Bereswill et al, 2010), hepatic fibrosis (Shu et al, 2007;Zeng et al, 2011), radiationinduced lung fibrosis , asthma (Ammar el et al, 2011), alcohol-induced liver disease (Nanji et al, 2003), non-alcoholic steatohepatitis (Ramirez-Tortosa et al, 2009), concanavalin A-induced liver injury (Tu et al, 2012), renal injury (Hashem et al, 2008;Pan et al, 2012), infection (Allam, 2009), fatigue (Gupta et al, 2009), bone turnover (Yang et al, 2011) and high-fat diet-induced hyperglycaemia (El-Moselhy et al, 2011). Curcumin has also been found to…”

Section: Suppression Of Tnf By Curcumin In Vivomentioning

confidence: 99%

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Aggarwal

Gupta

Sung

2013

British J Pharmacology

343

239

View full text Add to dashboard Cite

TNFs are major mediators of inflammation and inflammation-related diseases, hence, the United States Food and Drug Administration (FDA) has approved the use of blockers of the cytokine, TNF-a, for the treatment of osteoarthritis, inflammatory bowel disease, psoriasis and ankylosis. These drugs include the chimeric TNF antibody (infliximab), humanized TNF-a antibody (Humira) and soluble TNF receptor-II (Enbrel) and are associated with a total cumulative market value of more than $20 billion a year. As well as being expensive ($15 000-20 000 per person per year), these drugs have to be injected and have enough adverse effects to be given a black label warning by the FDA. In the current report, we describe an alternative, curcumin (diferuloylmethane), a component of turmeric (Curcuma longa) that is very inexpensive, orally bioavailable and highly safe in humans, yet can block TNF-a action and production in in vitro models, in animal models and in humans. In addition, we provide evidence for curcumin's activities against all of the diseases for which TNF blockers are currently being used. Mechanisms by which curcumin inhibits the production and the cell signalling pathways activated by this cytokine are also discussed. With health-care costs and safety being major issues today, this golden spice may help provide the solution. LINKED ARTICLESThis article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx

show abstract

“…The binding epitope for TNF is of mouse origin while the immunoglobulin G fragment is human based [16,51].…”

Section: Infliximabmentioning

confidence: 99%

“…It is a fully human anti-tumor necrosis factor-alpha monoclonal antibody which is produced by phage display technology [16,51].…”

Section: Adalimumabmentioning

confidence: 99%

Co-Morbidity of Cardiovascular Diseases and Rheumatoid Arthritis

Pandya

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic disease related to swelling of joints which lead to restriction in movement due to pain and deformity mainly in feet, ankle, wrist, and fingers. It is an autoimmune disease, and the manifestations caused due to its occurrence are not clearly understood. In today's time, it has been observed that comorbid conditions account for most of the deaths as they influence the outcome of RA and limit therapeutic options. The most common comorbid conditions which are diagnosed in RA patients are generally cardiovascular (CV) abnormalities, several infections, certain mental disorders, and malignancies. Among which CV comorbid diseases are the most common kind relating to disorders of heart and blood vessel that eventually leads to severe conditions such as angina, myocardial infarction, stroke, rheumatic heart disease, and many more. RA affects the quality of life of patients directly or indirectly, but it mainly shows a significant increase in the prevalence of CV diseases. Hence, it is essential to diagnose and understand about the related manifestations when one is suffering from RA. These studies will aid to make better treatment and management strategies. Hence, an attempt has been made in this review article regarding the epidemiology, impact of both diseases and related risk factors. It also gives information in brief about the pathological causes of the comorbidity and summarizes measures that may be used in the prevention and treatment of these conditions.

show abstract

Effects of Curcumin on Tumour Necrosis Factor‐α and Interleukin‐6 in the Late Phase of Experimental Acute Pancreatitis

Cited by 68 publications

References 32 publications

Antimicrobial effects of curcumin against L. monocytogenes, S. aureus, S. Typhimurium and E. coli O157:H7 pathogens in minced meat

Antimicrobial effects of curcumin against L. monocytogenes, S. aureus, S. Typhimurium and E. coli O157:H7 pathogens in minced meat

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Co-Morbidity of Cardiovascular Diseases and Rheumatoid Arthritis

Contact Info

Product

Resources

About